Asia-Pacific Stem Cell Market was worth USD 3310 million in 2018 and estimated to reach USD 5330 million by the end of 2023 with a CAGR of 10%. The allogeneic stem cell therapy is expected to command the largest share of the market in 2016. The market is expected to grow rapidly because of the extensive research and development which is being done. In the field of life sciences, one of the most promising markets at the moment is the global stem cell market and is expected to grow exponentially in the coming years as stem cells allow cost-effective treatment of many illnesses that currently have no or ineffective treatment.
Regenerative medicine is perhaps the most important use of stem cells, and other important areas include oncology, haematology, orthopaedics, cardiology and neurology. Another widely found application is drug discovery and development. Stem cells are kind of a research tool, as their in vitro study would allow scientists to understand in depth about the role of various organs and the development of particular illnesses; stem cells may also possibly allow drug developers to test emerging therapies on diseased cells. Stem cells therapy has shown substantial potential to treat cancer successfully. Cancer stem cells which have been tested on animals have shown satisfactory results.
Some of the key drivers of Asia-Pacific stem cell market are improved funding from various organizations for research and development for unmet medical needs, growing industry attention on stem cell research, and growing awareness across the world about stem cell therapies. Factors such as improving economic stability, better income, growing medical tourism in emerging countries such as India and China, patients from the U.S. and Europe opting for affordable yet quality treatment in these countries, thriving contract research industry, and high rate of chronic diseases is currently driving the stem cells market in Asia-Pacific region. While on the other hand, ethical issues are involved in the stem cells research and strict regulations to conduct trials on humans are some of the restraining factors. Also factors such as lack of required infrastructure and complications associated with the preservation of stem cell are limiting the growth of the stem cells market.
The stem cell market is segmented based on the treatment mode, cell types, applications, and technology. Treatment mode is segmented into allogeneic and autologous stem cell therapy. The cells type segment contains adult stem cells, induced pluripotent stem cells, human embryonic stem cells, and others. In the global stem cells market, the adult stem cells hold the highest share, while the market share of induced pluripotent stem cells is likely to grow in the next few years. The technology segment is divided into cell acquisition, cell production, cryopreservation and other sub-segments. On the basis of geography, the Asia-Pacific market is analysed under various regions namely India, China, Japan and South Korea. As of now, North America region dominates the global stem cells market. Europe comes next. However, the Asia-Pacific stem cell therapy market is expected to grow the fastest in this forecast period, mainly because of better regulatory support through encouraging government policies and increasing awareness among the public.
Some of the major players in this market are Athersys, StemCells Inc., Cryo Cell International, Geron Corporation, Mesoblast Ltd., Aastrom Biosciences Inc., Celgene Corporation, Invitrogen and Cytori Therapeutics Inc.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By mode of treatment
5.1.1 Autologous
5.1.2 Allogeneic
5.2 By application
5.2.1 CNS
5.2.2 CVS
5.2.3 GIT
5.2.4 Regenerative Medicine
5.2.5 Musculoskeletal
5.2.6 Eye & Immune System Development
5.2.7 Blood Disorders
5.3 By technology
5.3.1 Cell Acquisition
5.3.2 Cell Production
5.3.3 Cryopreservation
5.3.4 Expansion
5.3.5 Sub-Culture
5.4 By type
5.4.1 Adult Stem Cells
5.4.2 Human Embryonic Cells
5.4.3 Pluripotent Stem Cell
5.4.4 Natural Rosette Cells
6. Geographical Analysis
6.3 Asia-Pacific
6.1 Introduction
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Athersys
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 StemCells
8.3 Cryo Cell International
8.4 Geron Corporation
8.5 Mesoblast
8.6 Aastrom Biosciences
8.7 Celgene Corporation
8.8 Invitrogen
8.9 Cytori Therapeutics
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
